Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 14/20 | 0.59 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.58 |
| ▸ | KIF5B | P33176 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | TEK | Q02763 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17780957 | 0.99 | LCK (0.60) | LCKKDREGFRRETKIF5B | |
| SCHEMBL2481753 | 0.85 | LCK (0.66) | LCKKDREGFRRETKIF5B | |
| SCHEMBL6506857 | 0.84 | KDR (0.66) | LCKKDREGFRRETKIF5B | |
| SCHEMBL4360537 | 0.84 | KDR (0.65) | LCKKDREGFRRETKIF5B | |
| SCHEMBL23158504 | 0.83 | MET (0.61) | LCKKDREGFRRETKIF5B | |
| SCHEMBL5824492 | 0.83 | LCK (0.67) | LCKKDREGFRRETKIF5B | |
| SCHEMBL23457663 | 0.82 | LCK (0.74) | LCKKDREGFRRETKIF5B | |
| SCHEMBL5201680 | 0.81 | KDR (0.65) | LCKKDREGFRRETKIF5B | |
| SCHEMBL198505 | 0.80 | PDGFRB (0.68) | KDREGFRPDGFRAPDGFRBMET | |
| SCHEMBL4365791 | 0.80 | KDR (0.74) | LCKKDREGFRRETKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810596-B1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-11-30 | — | — | EP | disclosed |
| EP-3810596-A1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| CN-112513030-A | Quinoline derivatives as tyrosine kinase inhibitors | 里格尔药品股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-10851093-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851093-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2013097753-A1 | FUSED HETEROCYCLIC DERIVATIVE AND APPLICATION THEREOF | 江苏先声药业有限公司 (CN) | 2013-07-04 | — | — | WO | disclosed |
| WO-2005121125-A1 | ETHER-LINKED HETEROARYL COMPOUNDS | PFIZER INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851093-B2 | Tyrosine kinase inhibitors | TYRO3, RET, AXL | LCK 9/4885KDR 225/4885EGFR 36/4885 |
| US-20210078990-A1 | TYROSINE KINASE INHIBITORS | TYRO3, RET, AXL | LCK 9/4885KDR 225/4885EGFR 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.